Dorey A. Glenn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dorey A. Glenn has a total of 384 co-authors. Here are the top co-authors by number of shared publications:
Jarcy Zee
Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine at the University of Pennsylvania, Children's Hospital of Philadelphia Research Institute, Philadelphia, PA
8 shared publicationsAmy Mottl
University of North Carolina, Chapel Hill, North Carolina
6 shared publicationsKeisha Gibson
University of North Carolina, Chapel Hill, North Carolina
5 shared publicationsRonald Falk
University of North Carolina, Chapel Hill, North Carolina
5 shared publications- Keisha L. Gibson
University of North Carolina
4 shared publications Michelle R. Denburg
Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine at the University of Pennsylvania, Children's Hospital of Philadelphia Research Institute, Philadelphia, PA
4 shared publications
Latest Publications
- Open Access
- 10 July 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (10) , 2324-2334
Real-World Long-term Comparisons of Rituximab versus Calcineurin Inhibitors for Membranous Nephropathy in the Cure Glomerulonephropathy Study
Key Points: Comparative treatment effects for rituximab and calcineurin inhibitors on real-world long-term outcomes were estimated. Rituximab was associated with better preservation of long-term kidney function in Cure Glomerulonephropathy patients with membranous nephropathy. Treatments captured real-world prescribing practices, and observations pertain to a broad, pragmatic population relevant to clinical practice. Background: Clinical trials in rare glomerular disease may establish short-term treatment efficacy but are limited by small sample sizes and short study duration. Observational data are needed to assess longer-term outcomes and can provide insights into real-world prescribing practices. This study applied modern statistical methods to real-world data from the Cure Glomerulonephropathy network to compare the effectiveness of rituximab and calcineurin inhibitors on long-term primary membranous nephropathy outcomes. Methods: CureGN participants with biopsy-confirmed primary membranous nephropathy who initiated either of the two treatments at least 6 months after any previous immunosuppressant exposure were eligible. Inverse probability-of-treatment weighting balanced covariates at treatment initiation. Inverse probability-of-censoring weights accounted for censoring individuals if another immunosuppressant was started during follow-up. Outcomes included time from treatment initiation to composite kidney disease progression (40% decline in eGFR, KRT, or eGFR <15), proteinuria remission, and relapse following remission. Hazard ratios (HRs) and differences in restricted mean survival times were estimated. Results: In total, 325 treatment initiations across 250 unique participants were eligible, with a median follow-up of 53 months (25th–75th percentile: 24–79). Participants on calcineurin inhibitors had significantly higher risks of disease progression (HR=2.81; 95% confidence interval [CI], 1.16 to 6.80). HRs for proteinuria remission (HR=0.77; 95% CI, 0.50 to 1.17) and relapse (HR=1.42; 95% CI, 0.69 to 2.92) had wide CIs. Conclusions: Rituximab was associated with better kidney function preservation than calcineurin inhibitors over long follow-up. Proteinuria remission and relapse results favored rituximab but did not reach statistical significance. Long-term treatment comparative effectiveness in rare diseases can be evaluated with real-world data.
- 10 July 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (10) , 2324-2334
Open AccessReal-World Long-term Comparisons of Rituximab versus Calcineurin Inhibitors for Membranous Nephropathy in the Cure Glomerulonephropathy Study
Key Points: Comparative treatment effects for rituximab and calcineurin inhibitors on real-world long-term outcomes were estimated. Rituximab was associated with better preservation of long-term kidney function in Cure Glomerulonephropathy patients with membranous nephropathy. Treatments captured real-world prescribing practices, and observations pertain to a broad, pragmatic population relevant to clinical practice. Background: Clinical trials in rare glomerular disease may establish short-term treatment efficacy but are limited by small sample sizes and short study duration. Observational data are needed to assess longer-term outcomes and can provide insights into real-world prescribing practices. This study applied modern statistical methods to real-world data from the Cure Glomerulonephropathy network to compare the effectiveness of rituximab and calcineurin inhibitors on long-term primary membranous nephropathy outcomes. Methods: CureGN participants with biopsy-confirmed primary membranous nephropathy who initiated either of the two treatments at least 6 months after any previous immunosuppressant exposure were eligible. Inverse probability-of-treatment weighting balanced covariates at treatment initiation. Inverse probability-of-censoring weights accounted for censoring individuals if another immunosuppressant was started during follow-up. Outcomes included time from treatment initiation to composite kidney disease progression (40% decline in eGFR, KRT, or eGFR <15), proteinuria remission, and relapse following remission. Hazard ratios (HRs) and differences in restricted mean survival times were estimated. Results: In total, 325 treatment initiations across 250 unique participants were eligible, with a median follow-up of 53 months (25th–75th percentile: 24–79). Participants on calcineurin inhibitors had significantly higher risks of disease progression (HR=2.81; 95% confidence interval [CI], 1.16 to 6.80). HRs for proteinuria remission (HR=0.77; 95% CI, 0.50 to 1.17) and relapse (HR=1.42; 95% CI, 0.69 to 2.92) had wide CIs. Conclusions: Rituximab was associated with better kidney function preservation than calcineurin inhibitors over long follow-up. Proteinuria remission and relapse results favored rituximab but did not reach statistical significance. Long-term treatment comparative effectiveness in rare diseases can be evaluated with real-world data.
- Open Access
- 9 June 2026
- Published by S. Karger AG in Glomerular Diseases
- Vol. 6 (1) , 1-14
Acute Care Visits and Subsequent Health-Related Quality of Life among Children and Adults with Glomerular Disease in the Cure Glomerulonephropathy (CureGN) Cohort
Introduction: Health-related quality of life (HRQOL) is an important patient-reported aspect of overall health and is understudied in patients with glomerular disease (GD). Conflicting data have emerged regarding whether acute care visits (ACV) are associated with HRQOL. This report describes types of ACVs and their short-term impact on HRQOL in patients with minimal change disease (MCD), IgA nephropathy/vasculitis (IgAN/IgAV), focal segmental glomerulosclerosis (FSGS), and membranous nephropathy (MN). Methods: The Cure Glomerulonephropathy (CureGN) network is an observational prospective cohort study that has enrolled children and adults diagnosed with MCD, FSGS, MN, or IgAN/IgAV from 71 clinical centers across the United States, Canada, and Europe since December 2014. We used linear mixed effects models to examine the association between frequency of ACVs over a three-month period and subsequent Patient-Reported Outcomes Measurement Information System (PROMIS) scores, accounting for previous PROMIS scores, clinical characteristics, medication use, comorbid conditions, and socioeconomic indicators. Results: The study included 2,393 patients, 1,282 of whom experienced at least one ACV with a total of 3,555 ACVs (33.3 per 100 person-years) observed during CureGN study follow-up. The most frequent ACV-related diagnoses were categorized as infectious, gastrointestinal, hypertensive, or cardiovascular in origin. Two additional ACVs were associated with clinically and statistically significantly worse general physical health among adults; self-reported fatigue, mobility, and global health in children; and parent-reported fatigue, mobility, and global health in children. Only one additional ACV was associated with clinically and significantly worse fatigue among patients with cyclophosphamide exposure and parent-reported mobility among children ages 8 to <11. Conclusions: Increasing ACV burden was associated with lower HRQOL across multiple physical health domains for patients with GD. Our study reinforces the health care burden experienced by patients with GD and identifies risk factors for deterioration in HRQOL.
- 9 June 2026
- Published by S. Karger AG in Glomerular Diseases
- Vol. 6 (1) , 1-14
Open AccessAcute Care Visits and Subsequent Health-Related Quality of Life among Children and Adults with Glomerular Disease in the Cure Glomerulonephropathy (CureGN) Cohort
Introduction: Health-related quality of life (HRQOL) is an important patient-reported aspect of overall health and is understudied in patients with glomerular disease (GD). Conflicting data have emerged regarding whether acute care visits (ACV) are associated with HRQOL. This report describes types of ACVs and their short-term impact on HRQOL in patients with minimal change disease (MCD), IgA nephropathy/vasculitis (IgAN/IgAV), focal segmental glomerulosclerosis (FSGS), and membranous nephropathy (MN). Methods: The Cure Glomerulonephropathy (CureGN) network is an observational prospective cohort study that has enrolled children and adults diagnosed with MCD, FSGS, MN, or IgAN/IgAV from 71 clinical centers across the United States, Canada, and Europe since December 2014. We used linear mixed effects models to examine the association between frequency of ACVs over a three-month period and subsequent Patient-Reported Outcomes Measurement Information System (PROMIS) scores, accounting for previous PROMIS scores, clinical characteristics, medication use, comorbid conditions, and socioeconomic indicators. Results: The study included 2,393 patients, 1,282 of whom experienced at least one ACV with a total of 3,555 ACVs (33.3 per 100 person-years) observed during CureGN study follow-up. The most frequent ACV-related diagnoses were categorized as infectious, gastrointestinal, hypertensive, or cardiovascular in origin. Two additional ACVs were associated with clinically and statistically significantly worse general physical health among adults; self-reported fatigue, mobility, and global health in children; and parent-reported fatigue, mobility, and global health in children. Only one additional ACV was associated with clinically and significantly worse fatigue among patients with cyclophosphamide exposure and parent-reported mobility among children ages 8 to <11. Conclusions: Increasing ACV burden was associated with lower HRQOL across multiple physical health domains for patients with GD. Our study reinforces the health care burden experienced by patients with GD and identifies risk factors for deterioration in HRQOL.
- Open Access
- 18 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1813924
Humoral and cell mediated immune response to SARS-CoV-2 vaccination in patients with immune-mediated diseases
Background: Vaccination against SARS-CoV-2 induces an immune response that is protective against severe disease in healthy populations. However, humoral and cellular immune responses in individuals with immune-mediated diseases receiving immunosuppressive medications are not well understood. Methods: We conducted a single-center, prospective observational cohort study of pediatric and adult patients with vasculitis, glomerular disease, or other immune-mediated diseases. Antibody response assessed by viral neutralization and, in a subset, cellular immunity to SARS-CoV-2 vaccination were assessed before and at time points following initial and booster vaccination. Results: Between March 2021 and June 2022, 80 individuals with immune-mediated diseases and 12 healthy controls were enrolled and followed for a median of 11.97 months (IQR 7.64, 14.05). Following vaccination, the median percent angiotensin-converting enzyme 2 (ACE2) neutralization at V1 (1–3 months post vaccination) for patients in the immune-mediated disease cohort and healthy controls were 46.9% (IQR 0.65, 95.6) and 95.9% (IQR 94.6, 96.5), respectively. Of 26 individuals with anti-CD20 therapy exposure or laboratory evidence of B cell depletion at time of vaccination, only 11.9% had protective neutralization titers at V1. After adjustment for age, sex, BMI, race, vaccine type, and number of comorbidities, anti-CD20 exposure at time of initial vaccination remained significantly associated with a lower odds of ACE2 neutralization ≥30% at V1. The median T-ELISpot counts (RBD) at V1 for patients with immune-mediated diseases and healthy controls were comparable (16 [IQR 12, 37] and 16 [IQR 4.5, 23], respectively). Conclusions: Vaccination against SARS-CoV-2 during treatment with anti-CD20 antibody therapy was associated with impaired humoral immunity, but T cell responses were qualitatively preserved despite immunosuppressant exposure.
- 18 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1813924
Open AccessHumoral and cell mediated immune response to SARS-CoV-2 vaccination in patients with immune-mediated diseases
Background: Vaccination against SARS-CoV-2 induces an immune response that is protective against severe disease in healthy populations. However, humoral and cellular immune responses in individuals with immune-mediated diseases receiving immunosuppressive medications are not well understood. Methods: We conducted a single-center, prospective observational cohort study of pediatric and adult patients with vasculitis, glomerular disease, or other immune-mediated diseases. Antibody response assessed by viral neutralization and, in a subset, cellular immunity to SARS-CoV-2 vaccination were assessed before and at time points following initial and booster vaccination. Results: Between March 2021 and June 2022, 80 individuals with immune-mediated diseases and 12 healthy controls were enrolled and followed for a median of 11.97 months (IQR 7.64, 14.05). Following vaccination, the median percent angiotensin-converting enzyme 2 (ACE2) neutralization at V1 (1–3 months post vaccination) for patients in the immune-mediated disease cohort and healthy controls were 46.9% (IQR 0.65, 95.6) and 95.9% (IQR 94.6, 96.5), respectively. Of 26 individuals with anti-CD20 therapy exposure or laboratory evidence of B cell depletion at time of vaccination, only 11.9% had protective neutralization titers at V1. After adjustment for age, sex, BMI, race, vaccine type, and number of comorbidities, anti-CD20 exposure at time of initial vaccination remained significantly associated with a lower odds of ACE2 neutralization ≥30% at V1. The median T-ELISpot counts (RBD) at V1 for patients with immune-mediated diseases and healthy controls were comparable (16 [IQR 12, 37] and 16 [IQR 4.5, 23], respectively). Conclusions: Vaccination against SARS-CoV-2 during treatment with anti-CD20 antibody therapy was associated with impaired humoral immunity, but T cell responses were qualitatively preserved despite immunosuppressant exposure.
- Open Access
- 6 May 2026
- Published by Elsevier in Kidney Medicine
- Vol. 8 (7) , 101388
Blood Pressure Control in Adolescents With CKD and Risk of Kidney Failure in Young Adulthood
- 6 May 2026
- Published by Elsevier in Kidney Medicine
- Vol. 8 (7) , 101388
Open AccessBlood Pressure Control in Adolescents With CKD and Risk of Kidney Failure in Young Adulthood
- Open Access
- 15 May 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (7) , 1228-1229
Protecting Individuals with Kidney Disease from Vaccine Preventable Infections
An abstract is unavailable. This article is available as a PDF only.
- 15 May 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (7) , 1228-1229
Open AccessProtecting Individuals with Kidney Disease from Vaccine Preventable Infections
An abstract is unavailable. This article is available as a PDF only.
- 10 April 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (7) , 978-992
Proteinuria Trajectory and Disease Progression in Children and Adults with IgA Nephropathy/Vasculitis
Key Points: Defining risk of kidney function loss in IgA nephropathy and IgA vasculitis with nephritis is important for patient counseling and risk-based enrollment of clinical trials. Proteinuria trajectory over 2 years can uniquely identify patients at risk of loss of kidney function or kidney failure. Children and adults with the highest levels of proteinuria had a higher risk of progressive kidney disease compared with those with intermediate levels. Background: Identifying patients with IgA nephropathy at risk of disease progression is critical for clinical decision making, risk-based patient counseling, and optimal enrollment of clinical trials. Methods: Patients with IgA nephropathy and IgA vasculitis with nephritis were enrolled in the Cure Glomerulonephropathy Network, a multicenter observational cohort study. Children and adults were analyzed separately in four cohorts: (1) full, (2) incident, (3) prevalent, and (4) histology. Groups were defined using latent class trajectory modeling using proteinuria measurements over 2 years. Linear mixed models were used to calculate predicted eGFR slope. In adults, Cox proportional hazard models were used to model time to kidney failure or 40% eGFR decline as a function of the proteinuria trajectory group. Results: Of 919 patients with IgA nephropathy/IgA vasculitis with nephritis enrolled into the Cure Glomerulonephropathy Network, 368 adults and 234 children were included in the analysis. In the full adult cohort, group 1 had the lowest levels of proteinuria (interquartile range [IQR], 0.1–0.4 g/g), while groups 2 and 3 had intermediate and higher levels of proteinuria (IQR, 0.5–1.5 and IQR, 1.8–4.1 g/g), respectively. The average predicted time to eGFR 90, 16, and 8 years and >90, 67, and 11 years for proteinuria trajectory groups 1, 2, and 3 in the full adult and pediatric cohorts, respectively. In adults, adjusting for age, eGFR at enrollment, immunosuppression exposure, and hypertension, group 3 membership was associated with 3.13 (95% confidence interval [CI], 1.84 to 5.33), 1.98 (95% CI, 0.97 to 4.06), and 3.36 (95% CI, 1.59 to 7.13) times higher hazard of progressing to a composite outcome compared with group 2 membership in the full, prevalent, and histology cohorts, respectively, but not associated with progression in the incident cohort. Conclusions: Proteinuria trajectory is a major predictor of disease progression in patients with IgA nephropathy.
- 10 April 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (7) , 978-992
Proteinuria Trajectory and Disease Progression in Children and Adults with IgA Nephropathy/Vasculitis
Key Points: Defining risk of kidney function loss in IgA nephropathy and IgA vasculitis with nephritis is important for patient counseling and risk-based enrollment of clinical trials. Proteinuria trajectory over 2 years can uniquely identify patients at risk of loss of kidney function or kidney failure. Children and adults with the highest levels of proteinuria had a higher risk of progressive kidney disease compared with those with intermediate levels. Background: Identifying patients with IgA nephropathy at risk of disease progression is critical for clinical decision making, risk-based patient counseling, and optimal enrollment of clinical trials. Methods: Patients with IgA nephropathy and IgA vasculitis with nephritis were enrolled in the Cure Glomerulonephropathy Network, a multicenter observational cohort study. Children and adults were analyzed separately in four cohorts: (1) full, (2) incident, (3) prevalent, and (4) histology. Groups were defined using latent class trajectory modeling using proteinuria measurements over 2 years. Linear mixed models were used to calculate predicted eGFR slope. In adults, Cox proportional hazard models were used to model time to kidney failure or 40% eGFR decline as a function of the proteinuria trajectory group. Results: Of 919 patients with IgA nephropathy/IgA vasculitis with nephritis enrolled into the Cure Glomerulonephropathy Network, 368 adults and 234 children were included in the analysis. In the full adult cohort, group 1 had the lowest levels of proteinuria (interquartile range [IQR], 0.1–0.4 g/g), while groups 2 and 3 had intermediate and higher levels of proteinuria (IQR, 0.5–1.5 and IQR, 1.8–4.1 g/g), respectively. The average predicted time to eGFR 90, 16, and 8 years and >90, 67, and 11 years for proteinuria trajectory groups 1, 2, and 3 in the full adult and pediatric cohorts, respectively. In adults, adjusting for age, eGFR at enrollment, immunosuppression exposure, and hypertension, group 3 membership was associated with 3.13 (95% confidence interval [CI], 1.84 to 5.33), 1.98 (95% CI, 0.97 to 4.06), and 3.36 (95% CI, 1.59 to 7.13) times higher hazard of progressing to a composite outcome compared with group 2 membership in the full, prevalent, and histology cohorts, respectively, but not associated with progression in the incident cohort. Conclusions: Proteinuria trajectory is a major predictor of disease progression in patients with IgA nephropathy.
- Open Access
- 1 January 2025
- Published by S. Karger AG in Glomerular Diseases
- Vol. 5 (1) , 414-424
Pneumococcal Vaccine Use and Immunogenicity in Patients with Glomerular Disease: A Scoping Review and Analysis of Healthcare Claims Data
Introduction: Streptococcus pneumoniae infections are a preventable cause of morbidity and mortality in individuals with glomerular disease. There is limited immunogenicity data to inform the effectiveness of vaccination in this high-risk patient population. Methods: We conduct a scoping review of studies evaluating pneumococcal vaccine immunogenicity in adults and children with idiopathic nephrotic syndrome, focal segmental glomerulosclerosis, IgA vasculitis, or systemic lupus erythematosus with nephritis. We summarize patient characteristics, serotypes assessed, and rates of seroprotection and/or seroconversion. We then use the Merative MarketScan® Commercial Claims and Encounters database to describe rates of adequate, partial, and inadequate pneumococcal vaccination (PCV13 and/or PPSV23) within 12 months of incident glomerular disease diagnosis from 2010 to 2018. Results: A total of 879 citations were screened, of which 63 studies were reviewed for inclusion criteria. A final analytic set included 19 studies. Most studies reported clinically meaningful rates of seroprotection, though definitions varied widely across studies. In the analysis of commercial healthcare claims data, 1,343 children aged 2–11 years and 19,987 individuals aged 12 to <65 years with incident of GD were identified. Of those inadequately vaccinated prior to GD diagnosis, 4.0% (38/947) of the 2–11-year group and 6.8% (797/11,646) of those in the 12 to <65-year group were partially or adequately vaccinated within 12 months of diagnosis. Demographic and clinical factors more commonly identified in those with pneumococcal vaccination included sex, age, region, and prior influenza vaccination. Conclusion: There is limited literature describing pneumococcal vaccine immunogenicity in patients with glomerular disease. Metrics of reporting seroprotection and seroconversion to pneumococcal vaccines would benefit from standardization. Healthcare claims for pneumococcal vaccines following a diagnosis of glomerular disease suggest that efforts to improve timely vaccination are needed.
- 1 January 2025
- Published by S. Karger AG in Glomerular Diseases
- Vol. 5 (1) , 414-424
Open AccessPneumococcal Vaccine Use and Immunogenicity in Patients with Glomerular Disease: A Scoping Review and Analysis of Healthcare Claims Data
Introduction: Streptococcus pneumoniae infections are a preventable cause of morbidity and mortality in individuals with glomerular disease. There is limited immunogenicity data to inform the effectiveness of vaccination in this high-risk patient population. Methods: We conduct a scoping review of studies evaluating pneumococcal vaccine immunogenicity in adults and children with idiopathic nephrotic syndrome, focal segmental glomerulosclerosis, IgA vasculitis, or systemic lupus erythematosus with nephritis. We summarize patient characteristics, serotypes assessed, and rates of seroprotection and/or seroconversion. We then use the Merative MarketScan® Commercial Claims and Encounters database to describe rates of adequate, partial, and inadequate pneumococcal vaccination (PCV13 and/or PPSV23) within 12 months of incident glomerular disease diagnosis from 2010 to 2018. Results: A total of 879 citations were screened, of which 63 studies were reviewed for inclusion criteria. A final analytic set included 19 studies. Most studies reported clinically meaningful rates of seroprotection, though definitions varied widely across studies. In the analysis of commercial healthcare claims data, 1,343 children aged 2–11 years and 19,987 individuals aged 12 to <65 years with incident of GD were identified. Of those inadequately vaccinated prior to GD diagnosis, 4.0% (38/947) of the 2–11-year group and 6.8% (797/11,646) of those in the 12 to <65-year group were partially or adequately vaccinated within 12 months of diagnosis. Demographic and clinical factors more commonly identified in those with pneumococcal vaccination included sex, age, region, and prior influenza vaccination. Conclusion: There is limited literature describing pneumococcal vaccine immunogenicity in patients with glomerular disease. Metrics of reporting seroprotection and seroconversion to pneumococcal vaccines would benefit from standardization. Healthcare claims for pneumococcal vaccines following a diagnosis of glomerular disease suggest that efforts to improve timely vaccination are needed.
- 18 December 2024
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 85 (4) , 528-531
Glucocorticoid Exposure and Infection in Children and Adults With Glomerular Disease: Findings From the Cure Glomerulonephropathy Study
- 18 December 2024
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 85 (4) , 528-531
Glucocorticoid Exposure and Infection in Children and Adults With Glomerular Disease: Findings From the Cure Glomerulonephropathy Study
- Open Access
- 2 November 2023
- Published by Elsevier in Kidney International Reports
- Vol. 9 (2) , 257-265
Influenza Vaccine Administration and Effectiveness Among Children and Adults With Glomerular Disease
- 2 November 2023
- Published by Elsevier in Kidney International Reports
- Vol. 9 (2) , 257-265
Open AccessInfluenza Vaccine Administration and Effectiveness Among Children and Adults With Glomerular Disease
- Open Access
- 1 October 2022
- Published by Elsevier in Kidney Medicine
- Vol. 4 (11) , 100553
Immunosuppression Exposure and Risk of Infection-Related Acute Care Events in Patients With Glomerular Disease: An Observational Cohort Study
- 1 October 2022
- Published by Elsevier in Kidney Medicine
- Vol. 4 (11) , 100553
Open AccessImmunosuppression Exposure and Risk of Infection-Related Acute Care Events in Patients With Glomerular Disease: An Observational Cohort Study